|
breast cancer |
37 |
|
chinese |
21 |
|
oncology |
18 |
|
cancer |
9 |
|
colorectal cancer |
9 |
|
brca2 |
8 |
|
advanced breast cancer |
7 |
|
brca1 |
7 |
|
medical sciences |
7 |
|
microrna |
7 |
|
ovarian cancer |
7 |
|
pten |
7 |
|
adult oncology |
6 |
|
biomarkers |
6 |
|
breast cancer surgery |
6 |
|
breast neoplasms |
6 |
|
female |
6 |
|
hepatectomy |
6 |
|
humans |
6 |
|
liver cancer |
6 |
|
mental health |
6 |
|
metastases |
6 |
|
pediatric cardiology |
6 |
|
perceived need |
6 |
|
supportive care |
6 |
|
supportive care needs |
6 |
|
survival |
6 |
|
ventricular function |
6 |
|
acupuncture |
5 |
|
asian continental ancestry group - genetics |
5 |
|
attention bias |
5 |
|
biomarker |
5 |
|
brca2 protein - genetics |
5 |
|
breast cancer risk |
5 |
|
chemobrain |
5 |
|
chemotherapy |
5 |
|
chronic distress |
5 |
|
circulating microrna |
5 |
|
cogntivie bias |
5 |
|
esophageal cancer susceptibility gene |
5 |
|
gastric cancer |
5 |
|
hereditary breast and ovarian cancers |
5 |
|
hereditary breast cancer |
5 |
|
implementation study |
5 |
|
interpretation bias |
5 |
|
loss‐of‐function mutations |
5 |
|
mild cognitive impairment |
5 |
|
mutation |
5 |
|
palb2 mutation |
5 |
|
psychological distress |
5 |
|
stepped-care model |
5 |
|
survivorship |
5 |
|
symptom distress screening |
5 |
|
symptom management |
5 |
|
synthetic lethality |
5 |
|
trigeminal nerve stimulation |
5 |
|
activity impairment |
4 |
|
akt |
4 |
|
anthracycline |
4 |
|
antibodies, monoclonal, humanized - pharmacology |
4 |
|
antineoplastic agents - pharmacology |
4 |
|
anxiety |
4 |
|
attentional bias |
4 |
|
autophagy |
4 |
|
avoidance |
4 |
|
brca |
4 |
|
brca-negative |
4 |
|
breast neoplasms - blood - diagnosis - genetics - pathology |
4 |
|
breast neoplasms - drug therapy - enzymology - genetics - pathology |
4 |
|
breast neoplasms - genetics - pathology |
4 |
|
breast reconstruction |
4 |
|
colorectal neoplasms |
4 |
|
confirmatory factor analysis |
4 |
|
crc patients |
4 |
|
decisional conflict |
4 |
|
depression |
4 |
|
diagnostic marker |
4 |
|
dna methylation - genetics |
4 |
|
dna mutational analysis |
4 |
|
down-regulation - genetics |
4 |
|
drug resistance, neoplasm |
4 |
|
ductal carcinoma in situ |
4 |
|
employment |
4 |
|
ep4 |
4 |
|
erbb-2 |
4 |
|
fear of cancer recurrence |
4 |
|
fear of cancer recurrence trajectory |
4 |
|
genes, brca1 |
4 |
|
genes, brca2 |
4 |
|
her2-positive breast cancer |
4 |
|
hypermethylation |
4 |
|
intrusive thoughts |
4 |
|
killin |
4 |
|
membrane transport proteins - genetics |
4 |
|
metacognition |
4 |
|
metastatic disease |
4 |
|
methylation |
4 |
|
mir-92 |
4 |
|
mtor |
4 |
|
multigene panel |
4 |
|
neoadjuvant therapy |
4 |
|
neoplasm metastasis |
4 |
|
neuroticism |
4 |
|
nf-κb |
4 |
|
notch1 |
4 |
|
pathologic complete response |
4 |
|
patient satisfaction |
4 |
|
perceived needs |
4 |
|
pi3 kinase |
4 |
|
prospective studies |
4 |
|
psychometric assessement |
4 |
|
receptor, erbb-2 - antagonists & inhibitors - biosynthesis - genetics - metabolism |
4 |
|
recurrence |
4 |
|
return to work |
4 |
|
somatic mutations |
4 |
|
stomach neoplasms - blood - diagnosis - genetics - pathology |
4 |
|
survival analysis |
4 |
|
taxane |
4 |
|
tec |
4 |
|
thyroid cancer |
4 |
|
trajectory patterns |
4 |
|
trastuzumab |
4 |
|
unmet information needs |
4 |
|
validation |
4 |
|
work condition |
4 |
|
work productivity |
4 |
|
adjuvant chemotherapy |
3 |
|
aluscan sequencing |
3 |
|
animals |
3 |
|
asian |
3 |
|
atrial switch |
3 |
|
behavior change |
3 |
|
brain metastases |
3 |
|
brca mutation |
3 |
|
brca1 protein - genetics |
3 |
|
breast carcinoma |
3 |
|
breast neoplasm |
3 |
|
breast neoplasms - complications - diagnosis - surgery |
3 |
|
breast neoplasms - ethnology - genetics |
3 |
|
breast surgical consultation |
3 |
|
breast symptoms |
3 |
|
breast tumor |
3 |
|
cancer chemotherapy |
3 |
|
cancer classification |
3 |
|
cancer risk |
3 |
|
cancer staging |
3 |
|
carcinoma |
3 |
|
carcinoma - genetics - pathology |
3 |
|
carcinoma, lobular - complications - diagnosis - secondary - surgery |
3 |
|
cell cycle proteins - biosynthesis - genetics |
3 |
|
cell transformation, neoplastic - genetics |
3 |
|
chinese breast cancer |
3 |
|
chinese women |
3 |
|
chrysomya bezziana |
3 |
|
circulating cell-free mirna |
3 |
|
clonal evolution |
3 |
|
cns metastases |
3 |
|
cnv calling |
3 |
|
compound heterozygous mutations |
3 |
|
controlled study |
3 |
|
copy number variation |
3 |
|
decision aid |
3 |
|
diagnosis |
3 |
|
diagnostic imaging |
3 |
|
dietary change |
3 |
|
diptera |
3 |
|
dna repair - genetics |
3 |
|
dnmt3a |
3 |
|
european |
3 |
|
fanconi anemia |
3 |
|
founder effect |
3 |
|
genetic counseling |
3 |
|
genetic testing |
3 |
|
genetics |
3 |
|
health |
3 |
|
health service development |
3 |
|
interstitial loss of heterozygosity |
3 |
|
intraductal |
3 |
|
lapatinib |
3 |
|
large genmic rearrangements |
3 |
|
larva |
3 |
|
local ablative |
3 |
|
lymphatic metastasis |
3 |
|
machine learning |
3 |
|
mastectomy |
3 |
|
metastasis |
3 |
|
middle aged |
3 |
|
mir-143 |
3 |
|
mir-199a-5p |
3 |
|
mir-940 |
3 |
|
multiplex ligation-dependent probe amplification |
3 |
|
myiasis |
3 |
|
neratinib |
3 |
|
noninfiltrating |
3 |
|
obstetrics and gynecology |
3 |
|
older adults |
3 |
|
oncology nutrition |
3 |
|
oncoplastic surgery |
3 |
|
patient delay |
3 |
|
pilot-testing |
3 |
|
plasma |
3 |
|
precancer mutations |
3 |
|
psychosocial factors |
3 |
|
radiation |
3 |
|
screw worm infection - diagnosis - parasitology - surgery |
3 |
|
screwworm |
3 |
|
sentinel lymph node biopsy |
3 |
|
shared decision making |
3 |
|
single-nucleotide variation |
3 |
|
systemic ventricular function |
3 |
|
tetralogy of fallot |
3 |
|
tp53 mutation |
3 |
|
transposition of the great arteries |
3 |
|
treatment outcome |
3 |
|
triple-negative breast cancer |
3 |
|
tumor suppressor |
3 |
|
tyrosine kinase inhibitor |
3 |
|
variant of unknown significance |
3 |
|
vus |
3 |
|
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (nnk) |
2 |
|
acetylcholine receptors |
2 |
|
adipogenesis |
2 |
|
air travel |
2 |
|
anaplastic large cell lymphoma |
2 |
|
angiosarcoma |
2 |
|
antineoplastic agents - therapeutic use |
2 |
|
asia |
2 |
|
atypical ductal hyperplasia |
2 |
|
axillary dissection |
2 |
|
axillary surgery |
2 |
|
blood sampling |
2 |
|
body mass index |
2 |
|
bone scintiscanning |
2 |
|
brca1 gene |
2 |
|
brca1/2 |
2 |
|
breast - cancer - genetic aspects. |
2 |
|
breast - cancer - patients - china - hong kong. |
2 |
|
breast and ovarian cancer |
2 |
|
breast cancer progression |
2 |
|
breast cancer survival analysis |
2 |
|
breast conservation |
2 |
|
breast implant |
2 |
|
breast neoplasms - drug therapy - pathology - surgery |
2 |
|
breast neoplasms - genetics |
2 |
|
breast neoplasms, male |
2 |
|
breast surgery |
2 |
|
breast-cancer |
2 |
|
cancer cell |
2 |
|
cancer development |
2 |
|
cancer gene therapy |
2 |
|
cancer hormone therapy |
2 |
|
cancer screening |
2 |
|
cancer survival |
2 |
|
case report |
2 |
|
cathelicidin antimicrobia |
2 |
|
china |
2 |
|
chinese population |
2 |
|
chromosome 5 |
2 |
|
cilengitide |
2 |
|
clinical features |
2 |
|
communicable diseases |
2 |
|
complementary dna |
2 |
|
core needle biopsy |
2 |
|
cost effective |
2 |
|
covid-19 |
2 |
|
de novo metastatic breast cancer |
2 |
|
de novo mutation |
2 |
|
deep-vein thrombosis |
2 |
|
down regulation |
2 |
|
early detection of cancer |
2 |
|
early onset |
2 |
|
epidemiology |
2 |
|
face masks |
2 |
|
false-negative rate |
2 |
|
fibroadenoma |
2 |
|
flight |
2 |
|
gene |
2 |
|
gene expression |
2 |
|
gene targeting |
2 |
|
genes section |
2 |
|
germline mutation |
2 |
|
germline mutations |
2 |
|
glycolysis |
2 |
|
gpi |
2 |
|
haptoglobin |
2 |
|
healthcare survey |
2 |
|
hereditary breast |
2 |
|
hereditary breast and ovarian cancer syndrome |
2 |
|
high-intensity-focused ultrasound |
2 |
|
hong kong |
2 |
|
human |
2 |
|
incidence |
2 |
|
intraduct papilloma |
2 |
|
itgav |
2 |
|
learning curve |
2 |
|
local recurrence |
2 |
|
lymphatic mapping |
2 |
|
lymphedema |
2 |
|
lymphoedema |
2 |
|
mbc patients |
2 |
|
mendelian randomization |
2 |
|
messenger-rna decay |
2 |
|
micro rna |
2 |
|
mirn143 (alias) |
2 |
|
muscarinic receptors |
2 |
|
neoadjuvant chemotherapy |
2 |
|
nicotinic receptors |
2 |
|
occupational health hazard |
2 |
|
ovarian |
2 |
|
ovarian cancer syndrome |
2 |
|
overtreatment |
2 |
|
pathology |
2 |
|
patient acceptance |
2 |
|
pediatric breast cancer |
2 |
|
penetrance |
2 |
|
pertuzumab |
2 |
|
phyllodes tumuor of breast |
2 |
|
poly(adp-ribose) polymerase inhibitors |
2 |
|
practice guideline |
2 |
|
prediction |
2 |
|
prevalence |
2 |
|
prognosis |
2 |
|
quality of life |
2 |
|
rad51c |
2 |
|
rad51d |
2 |
|
recql mutation |
2 |
|
references (27) view in table layout |
2 |
|
reoperation - statistics and numerical data |
2 |
|
retinoblastoma |
2 |
|
retractor |
2 |
|
review |
2 |
|
risk factor |
2 |
|
risk factors |
2 |
|
rna analysis |
2 |
|
sars-cov-2 |
2 |
|
scintigraphy |
2 |
|
secretory breast cancer |
2 |
|
segmental |
2 |
|
sentinel lymph node |
2 |
|
sentinel node mapping |
2 |
|
shift work |
2 |
|
smoking |
2 |
|
stomach cancer |
2 |
|
surgery |
2 |
|
surgical margin |
2 |
|
surgical technique |
2 |
|
surgical wound |
2 |
|
systematic review |
2 |
|
target therapy |
2 |
|
targeted axillary dissection |
2 |
|
trial proposal |
2 |
|
triple negative breast cancer (tnbc) |
2 |
|
tumor associated macrophage |
2 |
|
tumor marker |
2 |
|
tumor microenvironment |
2 |
|
tumor-suppressor |
2 |
|
type 2 diabetes |
2 |
|
abdominal tissue |
1 |
|
acetaldehyde |
1 |
|
adjuvant |
1 |
|
adjuvant radiotherapy |
1 |
|
adjuvant therapy |
1 |
|
adjuvant treatment |
1 |
|
adolescent |
1 |
|
adult |
1 |
|
adverse outcome |
1 |
|
african ancestry |
1 |
|
age factors |
1 |
|
aged |
1 |
|
aged, 80 and over |
1 |
|
alanine aminotransferase blood level |
1 |
|
alcohol drinking |
1 |
|
aldehyde dehydrogenase‐2 |
1 |
|
ambulatory surgical procedures |
1 |
|
ambulatory surgical procedures - nursing |
1 |
|
anemia |
1 |
|
anesthesia |
1 |
|
anesthesia - nursing |
1 |
|
angiogenesis |
1 |
|
antibodies, monoclonal - administration and dosage |
1 |
|
antineoplastic combined chemotherapy protocols - adverse effects - therapeutic use |
1 |
|
apoptosis |
1 |
|
asian americans |
1 |
|
asian continental ancestry group |
1 |
|
asian continental ancestry group - psychology |
1 |
|
asian continental ancestry group - statistics and numerical data |
1 |
|
association |
1 |
|
autologous flap reconstruction |
1 |
|
bevacizumab |
1 |
|
binding site |
1 |
|
bioinformatics |
1 |
|
biopsy |
1 |
|
bipedicled abdominal flap |
1 |
|
brain metastasis |
1 |
|
brca gene |
1 |
|
brca1 and brca2 |
1 |
|
brca1/brca2 |
1 |
|
brca1/brca2 mutation carriers |
1 |
|
breast -- cancer -- china -- hong kong. |
1 |
|
breast -- cancer -- patients -- china -- hong kong. |
1 |
|
breast conservation therapy |
1 |
|
breast conservative treatment |
1 |
|
breast density |
1 |
|
breast imaging |
1 |
|
breast neoplasms - epidemiology |
1 |
|
breast neoplasms - epidemiology - genetics - metabolism |
1 |
|
breast neoplasms - epidemiology - pathology - therapy |
1 |
|
breast neoplasms - ethnology - pathology - therapy |
1 |
|
breast neoplasms - ethnology - psychology - surgery |
1 |
|
breast neoplasms - genetics - mortality - psychology - surgery |
1 |
|
breast neoplasms - genetics - prevention and control - surgery |
1 |
|
breast neoplasms - genetics - surgery |
1 |
|
breast neoplasms - metabolism - mortality |
1 |
|
breast neoplasms - pathology - radionuclide imaging - surgery |
1 |
|
breast neoplasms - pathology - surgery |
1 |
|
breast neoplasms - radiography |
1 |
|
breast neoplasms, male - genetics - prevention and control - surgery |
1 |
|
breast screening |
1 |
|
breast size |
1 |
|
cancer detection rate |
1 |
|
cancer risks |
1 |
|
cancer-predisposition syndromes |
1 |
|
candidate gene studies |
1 |
|
carcinoma in situ - ethnology - psychology - surgery |
1 |
|
carcinoma, ductal, breast - ethnology - psychology - surgery |
1 |
|
carcinoma, intraductal, noninfiltrating - pathology - surgery |
1 |
|
case-control matching |
1 |
|
choice behavior |
1 |
|
chromatin |
1 |
|
chromosomes, human, pair 12 - genetics |
1 |
|
chromosomes, human, pair 19 - genetics |
1 |
|
chromosomes, human, pair 9 - genetics |
1 |
|
complex indel |
1 |
|
comprehensive geriatric assessment |
1 |
|
consortium |
1 |
|
conventional dual tracer technique |
1 |
|
corynebacterium |
1 |
|
cosmetic outcome |
1 |
|
cost-effectiveness |
1 |
|
counseling |
1 |
|
decision making |
1 |
|
decision regret |
1 |
|
decision-making |
1 |
|
diep flap |
1 |
|
disease-free survival |
1 |
|
double heterozygosity |
1 |
|
ductoscopy |
1 |
|
early breast cancer |
1 |
|
early detection |
1 |
|
early-stage triple-negative breast cancer (etnbc) |
1 |
|
elderly |
1 |
|
estrogen receptors |
1 |
|
ethnicity |
1 |
|
european continental ancestry group - statistics and numerical data |
1 |
|
familial prostate cancer |
1 |
|
female surgeons |
1 |
|
fertility conservation |
1 |
|
first-line |
1 |
|
follow-up studies |
1 |
|
genetic counselling |
1 |
|
genetic screening |
1 |
|
genetic testing - utilization |
1 |
|
genetic variants |
1 |
|
genotype-phenotype correlations |
1 |
|
geography |
1 |
|
geriatric |
1 |
|
granuloma |
1 |
|
granulomatous lobular mastitis |
1 |
|
granulomatous mastitis |
1 |
|
health-related quality of life |
1 |
|
height |
1 |
|
her2 |
1 |
|
her2-oncogene |
1 |
|
her2-positive |
1 |
|
hereditary breast and ovarian cancer |
1 |
|
hereditary breast and ovarian cancer syndrome - genetics |
1 |
|
hereditary breast cancers |
1 |
|
high-risk women |
1 |
|
histologic grade |
1 |
|
hodgkin disease - radiotherapy |
1 |
|
hodgkin's disease |
1 |
|
hong kong - epidemiology |
1 |
|
idiopathic granulomatous mastitis |
1 |
|
image processing |
1 |
|
implant reconstruction |
1 |
|
inherited cancer genetics |
1 |
|
international collaboration |
1 |
|
international consortium |
1 |
|
intraductal carcinoma |
1 |
|
invasive disease-free survival (idfs) |
1 |
|
japan |
1 |
|
ldsc regression |
1 |
|
lymph node dissection |
1 |
|
lymphatic metastasis - pathology - radionuclide imaging |
1 |
|
lymphocytic infiltration |
1 |
|
lymphoscintigraphy |
1 |
|
male breast cancer |
1 |
|
male surgeons |
1 |
|
mammographic density |
1 |
|
mammographic density assessment |
1 |
|
mammography |
1 |
|
mass screening - statistics and numerical data |
1 |
|
mastectomy - methods |
1 |
|
mastectomy - mortality |
1 |
|
mastectomy, segmental |
1 |
|
mastectomy, segmental - methods |
1 |
|
mastitis |
1 |
|
medicine & public health |
1 |
|
menarche |
1 |
|
metastatic breast cancer |
1 |
|
methods |
1 |
|
microdochectomy |
1 |
|
missense variants |
1 |
|
molecular subtypes |
1 |
|
morbidity |
1 |
|
mortality |
1 |
|
neoadjuvant treatment |
1 |
|
neoplasm recurrence, local - drug therapy |
1 |
|
neoplasm recurrence, local - epidemiology |
1 |
|
neoplasm recurrence, local - prevention and control |
1 |
|
neoplasm staging |
1 |
|
neoplasm staging - methods |
1 |
|
neoplasms, radiation-induced - radiography |
1 |
|
neoplasms, second primary - radiography |
1 |
|
next-generation sequencing |
1 |
|
nipple discharge |
1 |
|
nodal marking |
1 |
|
occupational exposure - prevention & control - standards |
1 |
|
older chinese patients |
1 |
|
older patients |
1 |
|
oophorectomy |
1 |
|
oral contraceptives |
1 |
|
ovarian neoplasms |
1 |
|
ovarian neoplasms - epidemiology - genetics - metabolism |
1 |
|
ovarian neoplasms - genetics |
1 |
|
ovarian neoplasms - genetics - prevention and control - surgery |
1 |
|
pathogenic sequence variant |
1 |
|
pathology, surgical - standards |
1 |
|
patient acceptance of health care - statistics and numerical data |
1 |
|
patient preferences |
1 |
|
patient selection |
1 |
|
pembrolizumab |
1 |
|
pilot |
1 |
|
polymorphism, single nucleotide |
1 |
|
population surveillance |
1 |
|
postmastectomy |
1 |
|
pre-operative axillary ultrasound |
1 |
|
pregnancy |
1 |
|
preoperative care |
1 |
|
primary endocrine therapy |
1 |
|
primary prevention - statistics and numerical data |
1 |
|
prophylactic mastectomy |
1 |
|
prophylaxis |
1 |
|
prospective |
1 |
|
prostatic neoplasms |
1 |
|
prs |
1 |
|
psycho-oncology |
1 |
|
qualitative |
1 |
|
race/ethnicity |
1 |
|
radiation safety |
1 |
|
radiometry |
1 |
|
radiopharmaceuticals - diagnostic use |
1 |
|
re-evaluation |
1 |
|
receptor, erbb-2 - metabolism |
1 |
|
receptors, estrogen - metabolism |
1 |
|
receptors, progesterone - metabolism |
1 |
|
retrospective |
1 |
|
retrospective studies |
1 |
|
risk profiling |
1 |
|
risk-reducing surgery |
1 |
|
screening |
1 |
|
seer program |
1 |
|
sentinel lymph node (sln) |
1 |
|
sentinel lymph node biopsy - methods |
1 |
|
single nucleotide polymorphism |
1 |
|
skin stains |
1 |
|
snp |
1 |
|
snps |
1 |
|
southern chinese |
1 |
|
specimen handling - standards |
1 |
|
spect/ct |
1 |
|
subgroubs |
1 |
|
superparamagnetic iron oxide |
1 |
|
superparamagnetic iron oxide (spio) |
1 |
|
surgical oncology |
1 |
|
surgical treatment |
1 |
|
surveillance schemes |
1 |
|
survival outcome |
1 |
|
survival rate |
1 |
|
tamoxifen |
1 |
|
telephone |
1 |
|
tertiary care centers |
1 |
|
thrombocytopenia |
1 |
|
tram flap |
1 |
|
transheterozygosity |
1 |
|
treatment |
1 |
|
unclassified variant |
1 |
|
variant calling |
1 |
|
whole-brain irradiation |
1 |
|
whole-genome sequencing |
1 |
|
women's health |
1 |
|
work-life balance |
1 |